Terminated PHASE3 INTERVENTIONAL NCT00036231

Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction

Sponsor: Repligen Corporation

Conditions Autism

Interventions RG1068 (Synthetic Human Secretin)

Updated 5 times since 2017 Last updated: Nov 17, 2005 Started: Apr 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Repligen Corporation

Mitochondrial Diseases · Phase PHASE1

More terminations from Repligen Corporation

Other Autism trials with similar outcome

Browse all Autism trials

This PHASE3 trial investigates Autism and is currently terminated or withdrawn. Repligen Corporation leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Repligen Corporation

Data source: Repligen Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.